Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels

Journal of Lipid Research

Volumn 50, Issue 5, 2009, Pages 880-884

  Vaessen, S F C ^a   Dallinga Thie, G M ^a   Ross, C J D ^b   Splint, L J ^a   Castellani, L W ^c   Rensen, P C N ^d   Hayden, M R ^b   Schaap, F G ^a   Kuivenhoven, J A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chylomicron; Lipolysis; Lipoproteins; VLDL

Indexed keywords

APOLIPOPROTEIN A5; BINDING PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HYDROLYSIS; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN LIPID INTERACTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; GENETICS; HUMAN; MALE; MOUSE MUTANT;

ANIMALS; APOLIPOPROTEINS A; HUMANS; LIPOPROTEIN LIPASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; TRIGLYCERIDES;

EID: 67649697297     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800551-JLR200     Document Type: Article

References (30)

1. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
2. Pennacchio, L. A., M. Olivier, J. A. Hubacek, R. M. Krauss, E. M. Rubin, and J. C. Cohen. 2002. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum. Mol. Genet. 11: 3031-3038.
3. Mar, R., P. Pajukanta, H. Allayee, M. Groenendijk, G. Dallinga-Thie, R. M. Krauss, J. S. Sinsheimer, R. M. Cantor, T. W. de Bruin, and A. J. Lusis. 2004. Association of the APOLIPOPROTEIN A1/C3/A4/A5 gene cluster with triglyceride levels and LDL particle size in familial combined hyperlipidemia. Circ. Res. 94: 993-999.
4. Lai, C. Q., S. Demissie, L. A. Cupples, Y. Zhu, X. Adiconis, L. D. Parnell, D. Corella, and J. M. Ordovas. 2004. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J. Lipid Res. 45: 2096-2105.
5. Priore Oliva, C., L. Pisciotta, V. G. Li, M. P. Sambataro, A. Cantafora, A. Bellocchio, A. Catapano, P. Tarugi, S. Bertolini, and S. Calandra. 2005. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 25: 411-417.
6. Priore Oliva, C., F. Carubbi, F. G. Schaap, S. Bertolini, and S. Calandra. 2008. Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J. Intern. Med. 263: 450-458.
7. Dallinga-Thie, G. M., A. van Tol, H. Hattori, L. C. van Vark-van der Zee, H. Jansen, and E. J. Sijbrands. 2006. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia. 49: 1505-1511.
8. Vaessen, S. F., F. G. Schaap, J. A. Kuivenhoven, A. K. Groen, B. A. Hutten, S. M. Boekholdt, H. Hattori, M. S. Sandhu, S. A. Bingham, R. Luben, et al. 2006. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J. Lipid Res. 47: 2064-2070.
9. Kahri, J., J. Fruchart-Najib,N.Matikainen, J. C. Fruchart, J. Vakkilainen, and M. R. Taskinen. 2007. The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-Vand post-heparin plasma lipolytic activity. Diabetes Care. 30: 2083-2085.
10. Talmud, P. J., J. A. Cooper, H. Hattori, I. P. Miller, G. J. Miller, and S. E. Humphries. 2006. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia. 49: 2337-2340.
11. Alborn, W. E., M. J. Prince, and R. J. Konrad. 2007. Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes. Clin. Chim. Acta. 378: 154-158.
12. Wong, K., and R. O. Ryan. 2007. Characterization of apolipoprotein A-V structure and mode of plasma triacylglycerol regulation. Curr. Opin. Lipidol. 18: 319-324.
13. Becker, S., L. Schomburg, K. Renko, M. Tolle, M. van der Giet, and U. J. Tietge. 2006. Altered apolipoprotein A-V expression during the acute phase response is independent of plasma triglyceride levels in mice and humans. Biochem. Biophys. Res. Commun. 339: 833-839.
14. Hagerty, B. P., F. G. Schaap, M. Hermann, B. Krenn, C. Eder, B. Dorfmeister, H. Stangl, W. Patsch, and W. Strobl. 2008. Changes in hepatic ApoAV expression are not required for the rapid triglyceride lowering effect of fish oil diet in rats. Horm. Metab. Res. 40: 69-71.
15. Nelbach, L., X. Shu, R. J. Konrad, R. O. Ryan, and T. M. Forte. 2008. Effect of apolipoprotein A-V on plasma triglyceride, lipoprotein size, and composition in genetically engineered mice. J. Lipid Res. 49: 572-580.
16. Berbee, J. F., C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. Rensen. 2005. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL. J. Lipid Res. 46: 297-306.
17. Weinstein, M. M., A. P. Beigneux, B. S. Davies, P. Gin, L. Yin, K. Estrada, K. Melford, J. R. Bishop, J. D. Esko, L. G. Fong, et al. 2008. Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J. Biol. Chem. 283: 34511-34518.
18. Castellani, L. W., C. N. Nguyen, S. Charugundla, M. M. Weinstein, C. X. Doan, W. S. Blaner, N. Wongsiriroj, and A. J. Lusis. 2008. Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance. J. Biol. Chem. 283: 11633-11644.
19. Ross, C. J., J. Twisk, J.M. Meulenberg, G. Liu, K. van den Oever, E. Moraal, W. T. Hermens, J. Rip, J. J. Kastelein, J. A. Kuivenhoven, et al. 2004. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum. Gene Ther. 15: 906-919.
20. van der Vliet, H. N., M. G. Sammels, A. C. Leegwater, J. H. Levels, P. H. Reitsma, W. Boers, and R. A. Chamuleau. 2001. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J. Biol. Chem. 276: 44512-44520.
21. Schaap, F. G., P. C. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279: 27941-27947.
22. Merkel, M., B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren. 2005. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan bound lipoprotein lipase. J. Biol. Chem. 280: 21553-21560.
23. Lookene, A., J. A. Beckstead, S. Nilsson, G. Olivecrona, and R. O. Ryan. 2005. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J. Biol. Chem. 280: 25383-25387.
24. Nilsson, S. K., A. Lookene, J. A. Beckstead, J. Gliemann, R. O. Ryan, and G. Olivecrona. 2007. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry. 46: 3896-3904.
25. Weinstock, P. H., C.L. Bisgaier, K. Aalto-Setala, H. Radner, R. Ramakrishnan, S. Levak-Frank, A. D. Essenburg, R. Zechner, and J. L. Breslow. 1995. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96: 2555-2568.
26. Nilsson, S. K., S. Christensen, M. K. Raarup, R. O. Ryan, M. S. Nielsen, and G. Olivecrona. 2008. Endocytosis of apolipoprotein A-V by members of the low density lipoprotein receptor and the VPS10p domain receptor families. J. Biol. Chem. 283: 25920-25927.
27. O'Brien, P. J., W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad. 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51: 351-359.
28. Goldberg, I. J., C. A. Scheraldi, L. K. Yacoub, U. Saxena, and C. L. Bisgaier. 1990. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J. Biol. Chem. 265: 4266-4272.
29. Havel, R. J., J. P. Kane, and M. L. Kashyap. 1973. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J. Clin. Invest. 52: 32-38.
30. Merkel, M., and J. Heeren. 2005. Give me A5 for lipoprotein hydrolysis! J. Clin. Invest. 115: 2694-2696.